Dexmedetomidine Attenuated Neuron Death, Cognitive Decline, and Anxiety-Like Behavior by Inhibiting CXCL2 in CA1 Region of AD Mice [Corrigendum]

Ma K, An C, Li M, et al. Drug Des Devel Ther. 2024;18:5351—5365. The authors have advised due to an error that occurred inadvertently at the time of figure assembly, Figure 2 on page is incorrect. The trajectory map for the control group in Figure 2F is a duplication of the trajectory map in Figure 4E (AD+Dex group). The correct Figure 2 is as follows. Figure 2 Continued. Figure 2 Dex attenuates the abnormal behavior of AD mice. (A) Schematic of experimental design. Aβ was injected into mouse brains on day 0 (D0); 7 days after Aβ injection, Dex was injected for 7 days. (B) The body weight of each mouse from D0 to D17 is shown in the line chart; body weight of mice at D20 is shown in the bar chart (n = 4 in each group); the ratio of brain weight to body weight is shown in the last bar chart (n = 5 in control and AD + Dex T2 groups, n = 6 in AD and AD + Dex T1 groups). (C) Trajectory diagram in the open-field test for each group; total distance, average speed, distance in center zone, and time in center zone were calculated and are shown in the bar graph (n = 7 in control group, n = 6 in AD + Dex T1 group, n = 8 in AD and AD + Dex T1 groups). (D) Bar graph showing the number of marbles buried in each group (n = 12 in control group, n = 10 in AD and AD + Dex T1 group, n = 8 in AD + Dex T2 group). (E) The alternation triplet was calculated and shown in the bar graph (n = 7 in control group, n = 8 in AD and AD + Dex T1 groups). (F) The percentage of time exploring new objects was calculated and is shown in the bar graph (n = 9 in control and AD groups, n = 10 in AD + Dex T1 group). The authors apologize for this error and advise it does not affect the results and conclusions of the paper.